Growth and reproductive development are closely co-ordinated during puberty
but there is also evidence that growth hormone (GH) may have a physiologic
al role in adult ovarian function. Both GH and the insulin-like growth fact
ors (IGFs) have been shown to augment granulosa cell proliferation and ster
oidogenesis in the human Graafian follicle, suggesting that GH may act as a
'co-gonadotrophin' at ovarian level. Furthermore, the intra-ovarian 'IGF s
ystem' (i.e. IGFs and IGF-binding proteins) may be implicated in folicular
atresia and in disorders of follicular function associated with polycystic
ovary syndrome (PCOS). The clinical importance of GH to ovarian function in
the adult is illustrated by the finding that adjuvant GH treatment reduces
the dose of exogenous gonadotrophin which is required to induce folliculog
enesis in women with hypogonadotrophic hypogonadism. There is, however, no
evidence that GH supplementation is of significant clinical benefit in the
management of patients with other ovulatory disorders-including PCOS-or in
superovulation protocols for in vitro fertilzation.